Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients.
about
Recent developments in receptor tyrosine kinases targeted anticancer therapyProgress on antiangiogenic therapy for patients with malignant glioma.New approaches in angiogenic targeting for colorectal cancer.Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance)2D and 3D similarity landscape analysis identifies PARP as a novel off-target for the drug Vatalanib.Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant gliomaNeovascular age-related macular degeneration: opportunities for development of first-in-class biopharmaceuticals.Role of tyrosine kinase inhibitors in the management of high-grade gliomas.Bioanalytical aspects of clinical mass balance studies in oncology.Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors.Synthesis and cytotoxic evaluation of some new phthalazinylpiperazine derivatives.Biological effect of tyrosine kinase inhibitors on three canine mast cell tumor cell lines with various KIT statuses.Issues in the safety testing of metabolites.Inhibitory Effects of Red Wine on Lipid Oxidation in Fish Oil Emulsion and Angiogenesis in Zebrafish Embryo.
P2860
Q26751331-65EEB245-BC32-4971-9793-164423A91346Q33773189-652514BD-0B12-4599-AFFF-3FA115804AE3Q34382785-350DC3DD-ACD7-4F77-BB01-2298690E1926Q34570873-7A6A093D-08DE-4FA0-AD3A-F0FF519C1F26Q35786901-91958BFC-5142-467A-93B3-254C8B491192Q37214249-BA7CA605-995E-43F0-87FB-6387F604D7F4Q37882685-201D5587-1F35-4562-ABA1-6A5369B9A813Q37952242-64704FC8-1389-4240-AE78-43E1C09129F2Q37963912-4AF87E3C-5019-4B83-97D1-F7B798D4DD2BQ38552109-AC4D5575-F81A-476E-B4A7-19A5737E8E2BQ39456618-775C93A2-9B09-4F8B-8D17-7360B162F1EFQ39560865-FE4D07E8-5963-4B7D-B629-0B8242749049Q39934028-49B24A24-1A52-4F3F-9ABC-A92F2DC7857AQ50216641-D29C69F2-7170-47B1-850A-2FD71C639FDA
P2860
Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients.
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients.
@ast
Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients.
@en
Metabolism and disposition of vatalanib
@nl
type
label
Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients.
@ast
Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients.
@en
Metabolism and disposition of vatalanib
@nl
prefLabel
Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients.
@ast
Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients.
@en
Metabolism and disposition of vatalanib
@nl
P2093
P356
P1476
Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients.
@en
P2093
Antje Rottmann
Claire Souppart
Clemens Guenther
Dirk Laurent
Eric Masson
Felix Waldmeier
Gerhard Gross
Hans-Peter Gschwind
Karsten Denner
Lorenz M Jost
P304
P356
10.1124/DMD.106.009944
P577
2006-08-01T00:00:00Z